How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?

被引:0
作者
A Verma
J Pedicano
S Trifilio
S Singhal
M Tallman
J Winter
S Williams
L Gordon
J Monreal
J Mehta
机构
[1] Hematopoietic Stem Cell Transplant Program,Division of Hematology/Oncology
[2] The Feinberg School of Medicine,undefined
[3] The Robert H. Lurie Comprehensive Cancer Center,undefined
[4] Northwestern University,undefined
来源
Bone Marrow Transplantation | 2004年 / 33卷
关键词
autologous hematopoietic stem cell transplantation; engraftment; filgrastim; neutropenia; sargramostim;
D O I
暂无
中图分类号
学科分类号
摘要
Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ⩾0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients (Study Group), and compared their subsequent ANC to 108 historic controls who received growth factor longer. While ANC on the day after reaching 0.5 × 109/l was comparable between groups, ANC on the third day was significantly higher in the Control Group (2.3 vs 4.9 × 109/l; P=0.0003). When compared to the first day, ANC in the Study Group was higher by a median of 140% on the third day and by 450% in the Control Group (P=0.0002). A significantly higher proportion of patients experienced a decline in ANC after the first day in the Study Group. However, only one patient in the Study Group became neutropenic transiently and ANC recovered spontaneously the next day. The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC reaches 0.5 × 109/l, without compromising neutrophil recovery.
引用
收藏
页码:715 / 719
页数:4
相关论文
共 34 条
[1]  
Schmitz N(1995)Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation Bone Marrow Transplant 15 261-266
[2]  
Dreger P(1992)Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial Blood 80 1149-1157
[3]  
Zander AR(1995)Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study Ann Hematol 71 65-70
[4]  
Gorin NC(1996)Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study Bone Marrow Transplant 17 533-536
[5]  
Coiffier B(1997)Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas J Clin Oncol 15 1730-1735
[6]  
Hayat M(1997)G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day Bone Marrow Transplant 19 215-219
[7]  
Torres-Gomez A(1998)Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial Bone Marrow Transplant 21 369-373
[8]  
Jimenez MA(2002)Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 × 10 Bone Marrow Transplant 30 749-752
[9]  
Alvarez MA(2002)/L neutrophils on 3 consecutive days to define myeloid recovery Blood 100 417a-418a
[10]  
Faucher C(2003)Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation Bone Marrow Transplant 31 861-864